Diagnosis: X-ray
Staging: CT scan, PET scan and MRI
PET scan: FDG = fluorodeoxyglucose gets injected in the patient and it accumulate in
different tissues that have a high metabolism of glucose. Once it gets in the cell it does not
come out → ideal tracer to see witch tissues have a high metabolism.
- For patients with stage 1, 2 and 3
MRI: to be sure there is no disease in the brain
These scans lead to TNM classification:
- T (tumor) → size, number of lesions, ingrowth in organs
- N (lymph node) → higher lymp node, side of the body
- M (metastases) → how many lesions, in the same lung, further organs
→ All three factors are giving a number and this ‘code’ forms the stage.
Diagnosis:
Tumor biopsy: the tube/scope goes through the nose to the lungs
- Visual assessment
- Navigation options
o Radial EBUS (endobronchial ultrasound) → this is an echo machine; you can
see through the wall of the trachea, to see the Mediastinal Lymph Nodes that
are close to the trachea. Endoscopic ultrasound (EUS) is for the esophagus.
o Magnetic
o Fluorescence guided
o Virtual mapping
o → Not widespread
, Transthoracic punctures (when the tissue is too far for a biopsy): CT or US guided
- Very small biopsy → may miss
- Risks → pneumothorax: the air escapes and the lungs come loose from the chest and
the lungs collapse
For classification of diagnosis use:
- NSCLC (non-small cell long cancer)
- SCLC (small cell long cancer)
Therapy:
Early stage of the disease: local therapy
Locally advanced stage: use both local and
systemic therapies
Advanced stage: systemic therapy
Systemic therapy modalities:
- Chemotherapy
- Targeted therapy: a specific target has to be identified as the driver of the tumor,
start targeted therapy against this specific target (kinase inhibitors)
- Immunotherapy: if it works it works really well, but if it does not work it does not
work → select the right patients for this therapy (PD-L1)
o Pathological diagnostic algorithm: morphology, NGS, HE, IHC, FISH.
Approach to systemic treatment:
First line therapy (1L)
- First look for → oncogenic driver mutations (non-squamous)
o EGFR, ALK, BRAF, ROS1
o NTRK, RET
- If no oncogenic driver found → look at tumor PD-L1 expression
o If ≥50% → anti-PD-1 monotherapy (+/- chemo)
o If <50% → combination of chemotherapy and immunotherapy
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller Laurageerlings2000. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $4.34. You're not tied to anything after your purchase.